Marc Shuman

Title: The Innovations of Marc Shuman

Introduction

Marc Shuman is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of cancer research through his innovative inventions. With a total of 2 patents, Shuman's work focuses on the detection and staging of cancer, providing valuable tools for prognosis.

Latest Patents

Shuman's latest patents include the development of MT-SP1 polynucleotides and polypeptides. This invention introduces a novel membrane-type serine protease, designated MT-SP1, whose elevated expression is associated with cancer. One embodiment of this invention outlines a method for obtaining a prognosis or detecting and staging cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of MT-SP1 in the sample. An elevated level of this protease, compared to that in a biological sample from a normal healthy organism, indicates the presence or stage of cancer.

Career Highlights

Marc Shuman is currently associated with Catalyst Biosciences, Inc., where he continues to advance his research and innovations. His work has the potential to significantly impact cancer diagnostics and treatment.

Collaborations

Shuman has collaborated with notable colleagues, including Charles S. Craik and Toshihiko Takeuchi, enhancing the scope and depth of his research.

Conclusion

Marc Shuman's contributions to cancer research through his innovative patents demonstrate his commitment to improving diagnostic methods. His work continues to pave the way for advancements in the understanding and treatment of cancer.